Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117450) titled 'Romiplostim N01 for the treatment of cancer treatment-induced thrombocytopenia' on Jan. 23.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: Yidu Central Hospital of Weifang City
Condition:
cancer treatment-induced thrombocytopenia
Intervention:
Grade 4 thrombocytopenia:Leflunomide N01 recommended starting dose is 4 µg/kg, administered subcutaneously. The maximum dosage is 10 µg/kg once a week.
Patients with Grade 3 and Grade 2 thrombocytopenia:Eltrombopag NO1 recommended starting dose is 3 µg/kg, administered subcutaneously. The maximum dosage is once a ...